Article info
PDFCase report
Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe
- Correspondence to Dr Daniele Barbaro; danielebarbaro1970{at}libero.it
Citation
Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe
Publication history
- Accepted November 12, 2020
- First published December 22, 2020.
Online issue publication
January 25, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© BMJ Publishing Group Limited 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.